Extracellular Vesicles in Ocular Surface and Anterior Segment Medicine: Biological Roles, Therapeutic Applications, and Diagnostic Potential

Extracellular vesicles (EVs) are increasingly recognized as mediators of intercellular communication and as potential therapeutic and diagnostic platforms. In the ocular surface and anterior segment, EVs are released by epithelial, stromal, endothelial, immune, and aqueous outflow-related cells and are also detectable in tears and aqueous humor. Experimental studies suggest that EVs may promote corneal epithelial repair, modulate local immune responses, reduce stromal fibrosis, and participate in extracellular matrix regulation within the trabecular meshwork. In parallel, mesenchymal stromal cell-derived EVs are being investigated as cell-free therapeutics, while engineered EVs and EV–lipid hybrid systems may facilitate the delivery of nucleic acids and other therapeutic cargo to anterior segment tissues. Tear- and aqueous humor-derived EV preparations have also yielded candidate molecular signatures for ocular surface disease, glaucoma, and selected systemic disorders. However, much of the current evidence remains preclinical or exploratory. Reported effects are frequently based on conditioned medium, EV-enriched fractions, or incompletely characterized preparations, making it difficult to distinguish EV-specific activity from that of the broader secretome. Biomarker studies are additionally limited by small cohorts, low sample volumes, non-vesicular contaminants, and methodological heterogeneity. This review summarizes the biological roles, therapeutic applications, drug-delivery potential, and diagnostic use of EVs in anterior segment medicine. Particular emphasis is placed on the strength of EV-specific evidence, the limitations of extrapolating from non-ocular models, and the methodological, manufacturing, and regulatory requirements for clinical translation. EVs represent a promising interface between anterior segment biology, precision diagnosis, and targeted therapy, but rigorous characterization and comparative validation remain essential.

Authors

Institutions

Publication Details

Journal
Biologics
Published
2026-09-28
DOI
https://doi.org/10.3390/biologics6040028
Primary Topic
Extracellular vesicles in disease
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Extracellular Vesicles in Ocular Surface and Anterior Segment Medicine: Biological Roles, Therapeutic Applications, and Diagnostic Potential

Tomoko Tsukahara‐Kawamura, Toru Yasutake, Masatoshi Hirayama, Saya Oya et al.
Biologics
Extracellular vesicles in disease
article

Extracellular Vesicles in Ocular Surface and Anterior Segment Medicine: Biological Roles, Therapeutic Applications, and Diagnostic Potential

Tomoko Tsukahara‐Kawamura, Toru Yasutake, Masatoshi Hirayama, Saya Oya, Kimiko Tano, Ayumi Oka
article en

Abstract

Extracellular vesicles (EVs) are increasingly recognized as mediators of intercellular communication and as potential therapeutic and diagnostic platforms. In the ocular surface and anterior segment, EVs are released by epithelial, stromal, endothelial, immune, and aqueous outflow-related cells and are also detectable in tears and aqueous humor. Experimental studies suggest that EVs may promote corneal epithelial repair, modulate local immune responses, reduce stromal fibrosis, and participate in extracellular matrix regulation within the trabecular meshwork. In parallel, mesenchymal stromal cell-derived EVs are being investigated as cell-free therapeutics, while engineered EVs and EV–lipid hybrid systems may facilitate the delivery of nucleic acids and other therapeutic cargo to anterior segment tissues. Tear- and aqueous humor-derived EV preparations have also yielded candidate molecular signatures for ocular surface disease, glaucoma, and selected systemic disorders. However, much of the current evidence remains preclinical or exploratory. Reported effects are frequently based on conditioned medium, EV-enriched fractions, or incompletely characterized preparations, making it difficult to distinguish EV-specific activity from that of the broader secretome. Biomarker studies are additionally limited by small cohorts, low sample volumes, non-vesicular contaminants, and methodological heterogeneity. This review summarizes the biological roles, therapeutic applications, drug-delivery potential, and diagnostic use of EVs in anterior segment medicine. Particular emphasis is placed on the strength of EV-specific evidence, the limitations of extrapolating from non-ocular models, and the methodological, manufacturing, and regulatory requirements for clinical translation. EVs represent a promising interface between anterior segment biology, precision diagnosis, and targeted therapy, but rigorous characterization and comparative validation remain essential.

BiologicsVol. 6(4)
Fukuoka University (JP)
Good health and well-being
Openalex Percentile: Top 19%
Extracellular vesicles in disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.